ConvaTec Group PLC Board of Directors and Shareholder update (7872L)
September 08 2023 - 2:00AM
UK Regulatory
TIDMCTEC
RNS Number : 7872L
ConvaTec Group PLC
08 September 2023
This announcement contains inside information
Board of Directors and Shareholder update
Convatec Group PLC (the 'Company') announces that it has agreed,
with Novo Holdings A/S, to end the relationship agreement entered
into when Novo Holdings acquired their stake in the Company.
Consequently, Sten Scheibye will be stepping down from the Board.
These changes will take effect from today.
Novo Holdings said "Given the increasing momentum in Convatec's
growth and margin trajectory and the high regard and confidence we
have in management, we no longer feel a need to occupy a board
position at the Company. As shareholders, we are very excited by
the opportunity we see for further value creation by the
Company."
Commenting on behalf of the Board, the Chairman John McAdam said
"Sten has been a valued member of the Board over the last five
years and on behalf of the Group I would like to extend our thanks
for his contribution and insights. Novo Holdings remains an
important shareholder in Convatec and we look forward to continuing
our relationship and dialogue."
Sten Scheibye commented "I have very much enjoyed my time on
Convatec's Board. The Group has a clear strategy and strong
management team. I have no doubt that the Company will continue to
make significant progress in the future."
The person responsible for making this announcement is Robyn
Butler-Mason, Company Secretary.
LEI Code: 213800LS272L4FIDOH92
Contacts Analysts & Investors Kate Postans, Vice President of +44 (0) 7826 447807
Investor Relations & Corporate
Communications +44 (0) 7805 011046
Sheebani Chothani, Investor Relations ir@convatec.com
& Corporate Communications Manager
Buchanan: Charles Ryland / Chris
Media Lane +44 (0)207 466 5000
About Convatec
Pioneering trusted medical solutions to improve the lives
we touch : Convatec is a global medical products and technologies
company, focused on solutions for the management of chronic
conditions, with leading positions in advanced wound care,
ostomy care, continence care and infusion care. With around
10,000 colleagues, we provide our products and services in
almost 100 countries, united by a promise to be forever caring.
Our solutions provide a range of benefits, from infection prevention
and protection of at-risk skin, to improved patient outcomes
and reduced care costs. Group revenues in 2022 were over $2
billion. The company is a constituent of the FTSE 100 Index
(LSE:CTEC). To learn more about Convatec, please visit http://www.convatecgroup.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEAFNXEEEDEAA
(END) Dow Jones Newswires
September 08, 2023 02:00 ET (06:00 GMT)
Convatec (LSE:CTEC)
Historical Stock Chart
From Oct 2024 to Nov 2024
Convatec (LSE:CTEC)
Historical Stock Chart
From Nov 2023 to Nov 2024